**Additional File 1: SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents**

<table>
<thead>
<tr>
<th>Section/item</th>
<th>Item No</th>
<th>Description</th>
<th>Addressed on page number</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Administrative information</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym</td>
<td>P. 1 (title page)</td>
</tr>
<tr>
<td>Trial registration</td>
<td>2a</td>
<td>Trial identifier and registry name. If not yet registered, name of intended registry</td>
<td>P. 3 (end of abstract)</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>All items from the World Health Organization Trial Registration Data Set</td>
<td>All included in the trial registration at <a href="http://www.germanctr.de">http://www.germanctr.de</a></td>
</tr>
<tr>
<td>Protocol version</td>
<td>3</td>
<td>Date and version identifier</td>
<td>Included in the trial registration at <a href="http://www.germanctr.de">http://www.germanctr.de</a></td>
</tr>
<tr>
<td>Funding</td>
<td>4</td>
<td>Sources and types of financial, material, and other support</td>
<td>P. 19 (funding)</td>
</tr>
<tr>
<td>Roles and responsibilities</td>
<td>5a</td>
<td>Names, affiliations, and roles of protocol contributors</td>
<td>P. 1 (title page) and P. 19 (authors' contribution)</td>
</tr>
<tr>
<td>5b</td>
<td>Name and contact information for the trial sponsor</td>
<td>Included in the trial registration at <a href="http://www.german-ctr.de">http://www.german-ctr.de</a></td>
<td></td>
</tr>
<tr>
<td>5c</td>
<td>Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities</td>
<td>P. 19 (funding)</td>
<td></td>
</tr>
<tr>
<td>5d</td>
<td>Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)</td>
<td>P. 14 and 15 (documentation); P. 15 (assessment of safety); P. 15 (criteria for termination of the trial); P. 16 (Ethics and trial registration)</td>
<td></td>
</tr>
</tbody>
</table>

**Introduction**

**Background and rationale**

| 6a | Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention | P. 3 and 4 (background and rationale) |
| 6b | Explanation for choice of comparators | P. 4-6 (preliminary data) |

**Objectives**

| 7 | Specific objectives or hypotheses | P. 6 (objectives and hypotheses) |

**Trial design**

| 8 | Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) | P. 6 (design of the study and setting) |
Methods: Participants, interventions, and outcomes

Study setting 9  Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained  P. 6 (design of the study and setting)

Eligibility criteria 10  Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)  P. 7 and 8 (subject inclusion and exclusion criteria)

Interventions 11a  Interventions for each group with sufficient detail to allow replication, including how and when they will be administered  P. 9 and 10 (interventions)

11b  Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)  NA (intervention is of minimal risk, participants can withdraw at any time)

11c  Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)  P. 10 and 11 (evaluation)

11d  Relevant concomitant care and interventions that are permitted or prohibited during the trial  P. 10 and 11 (evaluation)

Outcomes 12  Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended  P. 10 and 11 (evaluation); Figure 2; Table 1

Participant timeline 13  Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)  P. 10 and 11 (evaluation); Figure 2; Table 1
| Sample size | 14 | Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations | P. 12-13 (sample size) |
| Recruitment | 15 | Strategies for achieving adequate participant enrolment to reach target sample size | P. 12-13 (sample size) |

**Methods: Assignment of interventions (for controlled trials)**

<table>
<thead>
<tr>
<th>Location:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sequence generation</td>
</tr>
<tr>
<td>Allocation concealment mechanism</td>
</tr>
<tr>
<td>Implementation</td>
</tr>
<tr>
<td>Blinding (masking)</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

**Methods: Data collection, management, and analysis**

| Data collection methods | 18a | Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (e.g., duplicate measurements, training of assessors) and a description of study instruments (e.g., questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol | P. 10 and 11 (evaluation); Table 1; Figure 2; P. 14 and 15 (documentation) |
18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols. P. 10 and 11 (evaluation); Table 1; Figure 2; P. 14 (handling of missing data); P. 14 and 15 (documentation);

Data management 19 Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol. P. 14 and 15 (documentation)

Statistical methods 20a Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol. P. 13 and 14 (statistical methods)

20b Methods for any additional analyses (eg, subgroup and adjusted analyses). P. 13 and 14 (statistical methods)

20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation). P. 13 and 14 (statistical methods)

Methods: Monitoring

Data monitoring 21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed. P. 14 and 15 (documentation); P. 15 (assessment of safety); P. 16 (criteria for termination of the trial)
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>21b</td>
<td>Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial</td>
<td>P. 9 and 10 (interventions); P. 16 (criteria for termination of the trial)</td>
</tr>
<tr>
<td>22</td>
<td>Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct</td>
<td>P. 15 (assessment of safety)</td>
</tr>
<tr>
<td>23</td>
<td>Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Plans for seeking research ethics committee/institutional review board (REC/IRB) approval</td>
<td>P. 18 (Ethics approval and consent to participate)</td>
</tr>
<tr>
<td>25</td>
<td>Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)</td>
<td>P. 16 (Ethics and trial registration)</td>
</tr>
<tr>
<td>26a</td>
<td>Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)</td>
<td>P. 9 (randomization)</td>
</tr>
<tr>
<td>26b</td>
<td>Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable</td>
<td>NA</td>
</tr>
<tr>
<td>27</td>
<td>How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial</td>
<td>P. 14 and 15 (documentation)</td>
</tr>
<tr>
<td>28</td>
<td>Financial and other competing interests for principal investigators for the overall trial and each study site</td>
<td>P. 19 (competing interests)</td>
</tr>
<tr>
<td>29</td>
<td>Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators</td>
<td>P. 14 and 15 (documentation)</td>
</tr>
</tbody>
</table>
Ancillary and post-trial care 30  Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation  NA

Dissemination policy 31a  Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions  P. 16 (Ethics and trial registration)

31b  Authorship eligibility guidelines and any intended use of professional writers  P. 16 (Ethics and trial registration)

31c  Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code  The study protocol is available under http://www.germanctr.de

Appendices

Informed consent materials 32  Model consent form and other related documentation given to participants and authorised surrogates  NA

Biological specimens 33  Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable  NA

It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported license.